Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a phase 3 trial. Caplyta ...

Johnson & Johnson has agreed to take over Intra-Cellular Therapies in a deal worth up to $14.6 billion – the second biopharma M&A announcement today. The $132-per-share agreement comes a few months ...

This title is part of a longer publication history. The full run of this journal will be searched. TITLE HISTORY A title history is the publication history of a journal and includes a listing of the ...

Decision-making inherently involves cause–effect relationships that introduce causal challenges. We argue that reliable algorithms for decision-making need to build upon causal reasoning. Addressing ...